4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported first quarter 2024 financial results and provided operational highlights.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks